{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Processa Pharmaceuticals, Inc.
Is Processa Pharmaceuticals, Inc. technically bullish or bearish?
As of June 20, 2025, Processa Pharmaceuticals, Inc. exhibits a neutral technical trend with mixed indicators, showing mild bullish momentum on weekly and monthly MACD but bearish signals from Bollinger Bands and daily moving averages, indicating no strong directional conviction.
Who are in the management team of Processa Pharmaceuticals, Inc.?
As of March 2022, the management team of Processa Pharmaceuticals, Inc. includes Dr. David Young as Chairman, CEO, and Founder, along with Directors Dr. Khalid Islam, Ms. Geraldine Pannu, Mr. Virgil Thompson, and Mr. Justin Yorke.
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing drug products to improve survival and quality of life for patients with unmet medical needs. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $3.09 million.
How big is Processa Pharmaceuticals, Inc.?
As of Jun 18, Processa Pharmaceuticals, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million, with a net profit of -11.95 million over the last four quarters. The balance sheet shows shareholder's funds of 1.70 million and total assets of 3.23 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
